Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
China Focus: China Releases Measures to Optimize COVID
CPC Leadership Makes Arrangements for Implementing Party Congress Guiding Principles
Xi Focus: Xi Calls for Scaling up Global Action on Wetlands Conservation As COP14 Opens
'Constantly learning' Imanaga off to impressive start with the Chicago Cubs
Xi Focus: Xi Steers Import Expo into Global Platform for Sharing Chinese Opportunities
Strengthening Building of Healthy Families
Promoting Children's Healthy Growth
Xi to Address 5th CIIE Opening Ceremony via Video, Speech to Be Broadcast Live
'The Apprentice,' about a young Donald Trump, premieres in Cannes
Xi to Address 5th CIIE Opening Ceremony via Video, Speech to Be Broadcast Live